FLT3 and myelodysplastic syndrome: Likewise, the first generation FLT3 inhibitor midostaurin failed to demonstrate superiority over single agent decitabine treatment in inducing CR/CRi and 1‐year OS in a cohort of 140 higher‐risk MDS/AML patients.106